Posttest - Tumor Board Tuesday - August 3, 2021 (ID: i788-15)

Question Title

* 1. Please list your first name, last name, and email:

First name:

Last name:

Email:

Question Title

* 2. What is your specialty?

Question Title

* 3. How many patients with pancreatic cancer do you treat each week?

1 to 10

11 to 25

26 to 50

I am not directly involved in patient care

Question Title

* 4. What percent of pancreatic adenocarcinomas harbor pathogenic/likely pathogenic BRAF gene alterations?

0.5%

1.5%

3.5%

5%

Question Title

* 5. Which pancreatic cancer subgroup is more likely to harbor BRAF gene alterations?

Ductal adenocarcinomas

Acinar cell carcinomas

Neuroendocrine cancers

Question Title

* 6. Of the following BRAF altered molecular subgroups, which is UNLIKELY to response to raf +/- mek inhibitors?

Exon 15 (e.g. BRAF V600E)

Exon 11 (e.g. BRAF N486_P490del)

Raf fusions

Kinase dead raf mutations